Peptide LibraryIcatibant dosage in published studies and labels
These are the doses used for Icatibant in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.
Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.
Last checked against primary sources:
Studied regimens and sources
Icatibant has an FDA-approved human dosage as Firazyr, for acute attacks of hereditary angioedema in adults aged 18 and older. The label dose is 30 mg by subcutaneous injection in the abdomen, repeated at intervals of at least 6 hours if the response is inadequate or symptoms return, with no more than 3 doses in 24 hours. Generic icatibant labels give the same dose.
| Human dosing established | Yes |
|---|---|
| Studied dose range | 30 mg per injection, up to 3 in 24 hours |
| Route | Subcutaneous |
| Frequency | As needed for an attack; repeat doses at least 6 hours apart, no more than 3 in 24 hours |
| Duration studied | Per attack |
| Half-life | Mean elimination half-life of 1.4 ± 0.4 hours after subcutaneous injection (Firazyr label) |
| Evidence level | FDA Approved |
| Last reviewed | 2026-11-07 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| FDA label — Firazyr, acute hereditary angioedema attacksFDA-approved label · FDA prescribing information | Adults aged 18 and older with hereditary angioedema | 30 mg | Subcutaneous, abdominal area, over at least 30 seconds | Once per attack; additional doses at least 6 hours apart if needed, maximum 3 in 24 hours | Per attack | Treatment of acute attacks of hereditary angioedema; studied in three controlled trials with 223 patients | FIRAZYR (icatibant) injection — FDA prescribing information, DailyMed |
| FDA label — Icatibant Injection (Teva), acute hereditary angioedema attacksFDA-approved label · FDA prescribing information | Adults aged 18 and older with hereditary angioedema | 30 mg | Subcutaneous, abdominal area | Additional doses at least 6 hours apart if needed, maximum 3 in 24 hours | Per attack | Treatment of acute attacks of hereditary angioedema | Icatibant Injection (Teva) — FDA prescribing information, DailyMed |
Where sources disagree
- Icatibant treats an attack once it has started; the label does not describe it as prevention between attacks. After treating a laryngeal attack, the label says to seek medical care right away because of the risk of airway obstruction.
- Safety and effectiveness in children under 18 have not been established, according to the label.
- Icatibant is supplied as a prefilled syringe delivering 30 mg in 3 mL (10 mg/mL), which patients may self-inject after training. DailyMed lists icatibant injection from several other companies as well as Firazyr.